Invanz
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
General Information
Invanz is a once-daily injectable antibiotic approved for use in
adults for the treatment of moderate to severe infections caused by
common gram-positive and gram-negative aerobic and anaerobic
bacteria. Included, are community-acquired pneumonia,
intra-abdominal, skin, urinary tract, kidney and post-surgical
gynecological infections.
Prior to administration, Invanz must be reconstituted and
diluted.
Clinical Results
The approval of Invanz is supported by studies conducted in more
than 1,900 subjects, in five infectious disease categories.
Treatment ranged from three to 14 days. Invanz exhibited an
excellent safety profile and showed success rates equivalent to
those of comparator antibiotics.
Side Effects
Adverse events associated with the use of Invanz may include
(but are not limited to) the following:
- Diarrhea
- Infused vein complications
- Nausea
- Headache
- Vaginitis in females
Mechanism of Action
Invanz (ertapenem sodium) is a structurally unique 1-(beta)
methyl-carbapenem related to a class of antibiotics known as
beta-lactams, which includes penicillins and cephalosporins. Invanz
works by blocking the formation of bacterial cell walls, thereby
causing cell death.
Additional Information
For additional information on Invanz, please visit
Invanz.
